Clinical Trial

Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data

Study acronym: META-RESPIRE
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are: Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes? Participants will: Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-09
Trial Details
NCT Number NCT07607080
Lead Sponsor Hospital del Mar Research Institute (IMIM)
Collaborators: Instituto de Salud Carlos III, Fundació La Marató de TV3, Hospital Universitari de Bellvitge, Hospital Universitari Joan XXIII de Tarragona., Parc Taulí Hospital Universitari, Institute for Bioengineering of Catalonia
Conditions Acute Hypoxemic Respiratory Failure
Enrollment 300 participants
Start Date 2026-06-04
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-08